

Oliver Peters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7452875/publications.pdf>

Version: 2024-02-01

161
papers

12,695
citations

57758

44
h-index

29157

104
g-index

183
all docs

183
docs citations

183
times ranked

17099
citing authors

#	ARTICLE	IF	CITATIONS
1	Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers. <i>Alzheimer's and Dementia</i> , 2023, 19, 487-497.	0.8	25
2	Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. <i>Alzheimer's and Dementia</i> , 2022, 18, 29-42.	0.8	24
3	Amyloid pathology but not <i>APOE</i> ϵ 4 status is permissive for tau-related hippocampal dysfunction. <i>Brain</i> , 2022, 145, 1473-1485.	7.6	17
4	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	9.0	97
5	Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment" data from the Dementia Competence Network. <i>Journal of Neural Transmission</i> , 2022, 129, 477-486.	2.8	14
6	Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer's disease. <i>Neuron</i> , 2022, 110, 1009-1022.e4.	8.1	27
7	Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimer's Disease Spectrum. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1267-1282.	2.6	12
8	Association Between Ginkgo Biloba Extract Prescriptions and Dementia Incidence in Outpatients with Mild Cognitive Impairment in Germany: A Retrospective Cohort Study. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-7.	2.6	3
9	Relevance of Subjective Cognitive Decline in Older Adults with a First-Degree Family History of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 545-555.	2.6	5
10	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	21.4	700
11	Characteristics of subjective cognitive decline associated with amyloid positivity. <i>Alzheimer's and Dementia</i> , 2022, 18, 1832-1845.	0.8	22
12	Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 652.	9.0	31
13	A Comparison of Operational Definitions for Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1663-1678.	2.6	4
14	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 614-628.	7.9	61
15	Abnormal Regional and Global Connectivity Measures in Subjective Cognitive Decline Depending on Cerebral Amyloid Status. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 493-509.	2.6	14
16	Association between composite scores of domain-specific cognitive functions and regional patterns of atrophy and functional connectivity in the Alzheimer's disease spectrum. <i>NeuroImage: Clinical</i> , 2021, 29, 102533.	2.7	15
17	Concomitants of Depressive Symptoms in Memory Clinic Patients. <i>GeroPsych: the Journal of Gerontopsychology and Geriatric Psychiatry</i> , 2021, 34, 37-44.	0.5	3
18	Hippocampal and Hippocampal-Subfield Volumes From Early-Onset Major Depression and Bipolar Disorder to Cognitive Decline. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 626974.	3.4	15

#	ARTICLE	IF	CITATIONS
19	Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age. <i>Neurology</i> , 2021, 96, .	1.1	72
20	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	12.8	140
21	Resting-State Network Alterations Differ between Alzheimer's Disease Atrophy Subtypes. <i>Cerebral Cortex</i> , 2021, 31, 4901-4915.	2.9	12
22	Overcoming barriers to the adoption of locating technologies in dementia care: a multi-stakeholder focus group study. <i>BMC Geriatrics</i> , 2021, 21, 378.	2.7	11
23	Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 537-547.	10.2	55
24	Presenilin 1 Gene Mutation (M139V) in a German Family with Early-Onset Alzheimer's Disease: A Case Report. <i>Archives of Clinical Neuropsychology</i> , 2021, , .	0.5	1
25	Cognitive profiles of patients with mild cognitive impairment due to Alzheimer's versus Parkinson's disease defined using a base rate approach: Implications for neuropsychological assessments. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12223.	2.4	4
26	A microRNA signature that correlates with cognition and is a target against cognitive decline. <i>EMBO Molecular Medicine</i> , 2021, 13, e13659.	6.9	29
27	Improving 3D convolutional neural network comprehensibility via interactive visualization of relevance maps: evaluation in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 191.	6.2	21
28	Memorability analysis for diagnostic photographs in cognitive assessment: Linking behavioral performance with biomarker status. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
29	Association between SCD-Plus features and GDS factors in subjective cognitive decline and healthy controls in the studies DELCODE and SILCODE. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
30	Cost of illness of apathy in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
31	Characterization of the NIA-AA Research Framework stage 2 in the longitudinal multicenter DELCODE study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
32	In vivo amyloid staging in individuals with subjective cognitive decline in DELCODE Study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
33	Prediction of amyloid-positivity in individuals with subjective cognitive decline: Machine learning approaches to optimize number-needed-to-screen. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
34	A rare heterozygous <i>TREM2</i> coding variant identified in familial clustering of dementia affects an intrinsically disordered protein region and function of TREM2. <i>Human Mutation</i> , 2020, 41, 169-181.	2.5	4
35	Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers—results from the DELCODE study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 131.	6.2	17
36	Value of Neuropsychological Tests to Identify Patients with Depressive Symptoms on the Alzheimer's Disease Continuum. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 819-826.	2.6	1

#	ARTICLE	IF	CITATIONS
37	Identification of a Cascade of Changes in Activities of Daily Living Preceding Short-Term Clinical Deterioration in Mild Alzheimer's Disease Dementia via Lead-Lag Analysis. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1005-1015.	2.6	0
38	Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients. <i>Alzheimer's and Dementia</i> , 2020, 16, 1504-1514.	0.8	35
39	Multimodal MRI analysis of basal forebrain structure and function across the Alzheimer's disease spectrum. <i>NeuroImage: Clinical</i> , 2020, 28, 102495.	2.7	17
40	Decreased cortical thickness in individuals with subjective cognitive decline with and without CSF A β pathology: Data from the DELCODE Study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044741.	0.8	1
41	Association of a CAMK2A genetic variant with logical memory performance and hippocampal volume in the elderly. <i>Brain Research Bulletin</i> , 2020, 161, 13-20.	3.0	3
42	Bupropion for the Treatment of Apathy in Alzheimer Disease. <i>JAMA Network Open</i> , 2020, 3, e206027.	5.9	18
43	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. <i>Acta Neuropathologica</i> , 2020, 139, 1025-1044.	7.7	40
44	Pursuing Experimental Reproducibility: An Efficient Protocol for the Preparation of Cerebrospinal Fluid Samples for NMR-Based Metabolomics and Analysis of Sample Degradation. <i>Metabolites</i> , 2020, 10, 251.	2.9	6
45	Minor neuropsychological deficits in patients with subjective cognitive decline. <i>Neurology</i> , 2020, 95, e1134-e1143.	1.1	58
46	Apolipoprotein E4 disrupts the neuroprotective action of sortilin in neuronal lipid metabolism and endocannabinoid signaling. <i>Alzheimer's and Dementia</i> , 2020, 16, 1248-1258.	0.8	18
47	Plasma Amyloid Concentration in Alzheimer's Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer's Disease Cases from Controls. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1285-1294.	2.6	20
48	Value of a Panel of 6 Serum Biomarkers to Differentiate Between Healthy Controls and Mild Cognitive Impairment Due to Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2020, 34, 318-324.	1.3	7
49	Human endogenous retrovirus HERV-K(HML-2) RNA causes neurodegeneration through Toll-like receptors. <i>JCI Insight</i> , 2020, 5, .	5.0	68
50	Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease. <i>Molecular Systems Biology</i> , 2020, 16, e9356.	7.2	157
51	Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 66.	6.2	74
52	Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimer's disease. <i>PLoS ONE</i> , 2019, 14, e0218111.	2.5	23
53	A combined miRNA-piRNA signature to detect Alzheimer's disease. <i>Translational Psychiatry</i> , 2019, 9, 250.	4.8	74
54	Configuration in smart service systems: A practice-based inquiry. <i>Information Systems Journal</i> , 2019, 29, 1256-1292.	6.9	19

#	ARTICLE	IF	CITATIONS
55	Memorability of photographs in subjective cognitive decline and mild cognitive impairment: Implications for cognitive assessment. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 610-618.	2.4	17
56	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , The, 2019, 18, 1034-1044.	10.2	85
57	Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 8.	6.2	23
58	Structural integrity in subjective cognitive decline, mild cognitive impairment and Alzheimer's disease based on multicenter diffusion tensor imaging. <i>Journal of Neurology</i> , 2019, 266, 2465-2474.	3.6	35
59	Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 33.	6.2	30
60	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	21.4	1,962
61	THE APOE- ϵ 4 ALLELE AND AGE SYNERGISTICALLY DRIVE DISEASE PROGRESSION IN ALZHEIMER'S DISEASE. <i>Innovation in Aging</i> , 2019, 3, S943-S943.	0.1	0
62	ICAD122: ALTERATIONS OF INTRINSIC CONNECTIVITY IN POSTERIOR DEFAULT MODE NETWORK ACROSS AT RISK STAGES OF ALZHEIMER'S DEMENTIA. <i>Alzheimer's and Dementia</i> , 2019, 15, P101.	0.8	0
63	ICAD28: PATTERNS OF INCREASED AND DECREASED PRECLINICAL FUNCTIONAL CONNECTIVITY IN SCD DEPENDING ON AMYLOID STATUS. <i>Alzheimer's and Dementia</i> , 2019, 15, P35.	0.8	0
64	ICAD16: CORTICAL AMYLOID BURDEN CORRELATES WITH ATROPHY OF THE POSTERIOR PART OF THE NUCLEUS BASALIS MEYNERT IN AMYLOID-POSITIVE SCD. <i>Alzheimer's and Dementia</i> , 2019, 15, P25.	0.8	0
65	Cognitive behavioural therapy for the treatment of late life depression: study protocol of a multicentre, randomized, observer-blinded, controlled trial (CBTlate). <i>BMC Psychiatry</i> , 2019, 19, 423.	2.6	11
66	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease—Data from three memory clinic studies. <i>Alzheimer's and Dementia</i> , 2019, 15, 185-193.	0.8	28
67	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. <i>Brain</i> , 2018, 141, 1186-1200.	7.6	83
68	Methods in endogenous steroid profiling — A comparison of gas chromatography mass spectrometry (GC-MS) with supercritical fluid chromatography tandem mass spectrometry (SFC-MS/MS). <i>Journal of Chromatography A</i> , 2018, 1554, 101-116.	3.7	41
69	Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE). <i>Alzheimer's Research and Therapy</i> , 2018, 10, 15.	6.2	131
70	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β 2 positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.8	58
71	Association of Cerebral Amyloid- β 2 Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	11.0	133
72	P1379: CORTICAL THINNING IN SUBJECTIVE COGNITIVE DECLINE WITH AND WITHOUT AD PATHOLOGY: DATA FROM THE DELCODE STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P443.	0.8	0

#	ARTICLE	IF	CITATIONS
73	P3â€³27: NEUROPSYCHIATRIC SYMPTOMS IN ATâ€³RISK GROUPS FOR AD DEMENTIA AND THEIR RELATION TO AD BIOMARKERS: DATA FROM THE DELCODE STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1206.	0.8	0
74	P2â€³455: STRUCTURAL INTEGRITY IN SUBJECTIVE COGNITIVE DECLINE, MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: RESULTS FROM THE DELCODE STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P894.	0.8	0
75	P4â€³142: HOW RELATIONSHIP DYNAMICS BETWEEN PERSONS WITH DEMENTIA AND CAREGIVERS REGARDING SUBJECTIVE TECHNOLOGICAL AFFINITY WITH LOCATING SYSTEMS PLAY OUT OVER TIME. <i>Alzheimer's and Dementia</i> , 2018, 14, P1493.	0.8	0
76	P3â€³366: MULTICENTER RESTING STATE FUNCTIONAL CONNECTIVITY IN PRODROMAL AND DEMENTIA STAGES OF ALZHEIMER'S DISEASE: RESULTS FROM THE DZNE DELCODE STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1228.	0.8	0
77	ICâ€³Pâ€³155: STRUCTURAL INTEGRITY IN SUBJECTIVE COGNITIVE DECLINE, MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: RESULTS FROM THE DELCODE STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P131.	0.8	0
78	P1â€³140: A GENERIC LATENT VARIABLE APPROACH FOR MEASURING COGNITIVE RESERVE: PHENOTYPE VALIDATION AND GENETIC ASSOCIATION RESULTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P328.	0.8	0
79	P3â€³591: A GERMAN VERSION OF THE LIFETIME OF EXPERIENCES QUESTIONNAIRE (LEQ) TO MEASURE COGNITIVE RESERVE: VALIDATION RESULTS FROM THE DELCODE STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1352.	0.8	8
80	CORRELATION OF CSF- AND MRI-BIOMARKERS AND PROGRESSION OF COGNITIVE DECLINE IN AN OPEN LABEL MCI TRIAL. <i>Journal of prevention of Alzheimer's disease, The</i> , 2018, 5, 1-5.	2.7	5
81	Exploring Genetic Associations of Alzheimerâ€™s Disease Loci With Mild Cognitive Impairment Neurocognitive Endophenotypes. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 340.	3.4	12
82	Computerâ€³assisted prediction of clinical progression in the earliest stages of AD. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 726-736.	2.4	8
83	Beyond surgery: clinical and economic impact of Enhanced Recovery After Surgery programs. <i>BMC Health Services Research</i> , 2018, 18, 1008.	2.2	33
84	User experience and clinical effectiveness with two wearable global positioning system devices in home dementia care. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 636-644.	3.7	27
85	Golgin A4 in CSF and granulovacuolar degenerations of patients with Alzheimer disease. <i>Neurology</i> , 2018, 91, e1799-e1808.	1.1	11
86	CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 782-790.	2.4	26
87	Neurogranin and BACE1 in CSF as Potential Biomarkers Differentiating Depression with Cognitive Deficits from Early Alzheimerâ€™s Disease: A Pilot Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2018, 8, 277-289.	1.3	20
88	Distinct expression of the neurotoxic microRNA family let-7 in the cerebrospinal fluid of patients with Alzheimer's disease. <i>PLoS ONE</i> , 2018, 13, e0200602.	2.5	115
89	Prominent Non-Memory Deficits in Alzheimerâ€™s Disease Are Associated with Faster Disease Progression. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1029-1039.	2.6	14
90	Multicenter Resting State Functional Connectivity in Prodromal and Dementia Stages of Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 801-813.	2.6	19

#	ARTICLE	IF	CITATIONS
91	Histopathology and Florbetaben PET in Patients Incorrectly Diagnosed with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 441-446.	2.6	9
92	Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts. <i>Alzheimer's and Dementia</i> , 2017, 13, 1226-1236.	0.8	59
93	Technology for home dementia care: A prototype locating system put to the test. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 332-338.	3.7	25
94	Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 939-950.	2.6	74
95	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 33-40.	3.1	27
96	Tau plasma levels in subjective cognitive decline: Results from the DELCODE study. <i>Scientific Reports</i> , 2017, 7, 9529.	3.3	27
97	Rare coding variants in <i>PLCG2</i> , <i>ABI3</i> , and <i>TREM2</i> implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	21.4	783
98	Prediction of Alzheimer's Dementia in Patients with Amnesic Mild Cognitive Impairment in Clinical Routine: Incremental Value of Biomarkers of Neurodegeneration and Brain Amyloidosis Added Stepwise to Cognitive Status. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 373-388.	2.6	15
99	Correlation of florbetaben PET imaging and the amyloid peptide A β 42 in cerebrospinal fluid. <i>Psychiatry Research - Neuroimaging</i> , 2017, 265, 98-101.	1.8	11
100	[P2-390]: LOCAL AND GLOBAL RESTING STATE ALTERATIONS IN DIFFERENT STAGES DURING THE DEVELOPMENT OF ALZHEIMER'S DISEASE AS DEMONSTRATED IN THE DZNE DELCODE COHORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P779.	0.8	1
101	[P3-218]: TAU PLASMA LEVELS IN SUBJECTIVE COGNITIVE DECLINE: RESULTS FROM THE DELCODE STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1021.	0.8	1
102	[P3-437]: LATENT FACTOR STRUCTURE OF THE DELCODE STUDY NEUROPSYCHOLOGICAL TEST BATTERY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1136.	0.8	2
103	[P1-122]: WHAT IS MEMORABLE IS CONSERVED ACROSS HEALTHY AGING, EARLY ALZHEIMER'S DISEASE, AND NEURAL NETWORKS. <i>Alzheimer's and Dementia</i> , 2017, 13, P287.	0.8	2
104	[P4-139]: APPLICATION OF THE A/T/N BIOMARKER CLASSIFICATION SYSTEM IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: CONVERSION RATES TO AD AND OTHER DEMENTIAS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1310.	0.8	0
105	[TD-18]: A LONGITUDINAL USER STUDY TESTING TWO LOCATING SYSTEMS IN HOME DEMENTIA CARE. <i>Alzheimer's and Dementia</i> , 2017, 13, P165.	0.8	2
106	[P4-532]: OBJECT AND SCENE MEMORY ARE DIFFERENTIALLY ASSOCIATED WITH CSF MARKERS OF ALZHEIMER'S DISEASE AND MRI VOLUMETRY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1553.	0.8	0
107	Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 84.	6.2	58
108	P4-174: Evaluation of Cutoff Values For Fully Automated Hippocampus Volumetry With Fsl-First For Prediction Of Alzheimer's Disease Dementia In Mci Subjects. , 2016, 12, P1084-P1085.		0

#	ARTICLE	IF	CITATIONS
109	No association of the variant rs11887120 in DNMT3A with cognitive decline in individuals with mild cognitive impairment. <i>Epigenomics</i> , 2016, 8, 593-598.	2.1	5
110	Combination of Structural MRI and $\text{^{18}F}$ -FDG-PET of the Brain Improves Diagnostic Accuracy in Newly Manifested Cognitive Impairment in Geriatric Inpatients. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1319-1331.	2.6	9
111	Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2016, 12, 872-881.	0.8	50
112	Validation of the Erlangen Score Algorithm for the Prediction of the Development of $\text{^{\wedge}}$ Dementia due to Alzheimer's Disease in $\text{^{\wedge}}$ Pre-Dementia Subjects. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 433-441.	2.6	41
113	The Latent Dementia Phenotype $\hat{\Gamma}$ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 547-560.	2.6	23
114	Identification and Characterization of Circular RNAs As a New Class of Putative Biomarkers in Human Blood. <i>PLoS ONE</i> , 2015, 10, e0141214.	2.5	542
115	Combined treatment with memantine and galantamine $\text{^{\wedge}}$ CR compared $\text{^{\wedge}}$ with galantamine $\text{^{\wedge}}$ CR only in antidementia drug naïve patients with mild $\text{^{\wedge}}$ to $\text{^{\wedge}}$ moderate Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2015, 1, 198-204.	3.7	25
116	The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 1605.e13-1605.e20.	3.1	27
117	Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type. <i>Neurobiology of Aging</i> , 2015, 36, 601-607.	3.1	125
118	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. <i>Brain</i> , 2015, 138, 1327-1338.	7.6	284
119	Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI. <i>Neurology</i> , 2015, 84, 1261-1268.	1.1	41
120	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	7.4	1,166
121	Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimer's disease: a voxel-based lesion mapping study. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 27.	6.2	13
122	Alzheimer Amyloid Peptide $\text{^{\wedge}}$ 242 Regulates Gene Expression of Transcription and Growth Factors. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 613-624.	2.6	47
123	PLD3 in non-familial Alzheimer's disease. <i>Nature</i> , 2015, 520, E3-E5.	27.8	58
124	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. <i>Alzheimer's and Dementia</i> , 2015, 11, 195.	0.8	56
125	Memory Concerns, Memory Performance and Risk of Dementia in Patients with Mild Cognitive Impairment. <i>PLoS ONE</i> , 2014, 9, e100812.	2.5	41
126	The rare $\text{^{\wedge}}$ TREM2 $\text{^{\wedge}}$ R47H variant exerts only a modest effect on Alzheimer disease risk. <i>Neurology</i> , 2014, 83, 1353-1358.	1.1	40

#	ARTICLE	IF	CITATIONS
127	SUCLG2 identified as both a determinant of CSF A β 1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. <i>Human Molecular Genetics</i> , 2014, 23, 6644-6658.	2.9	45
128	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. <i>Neurobiology of Aging</i> , 2014, 35, 2657.e13-2657.e19.	3.1	34
129	Genetic interaction of <i>PICALM</i> and <i>APOE</i> is associated with brain atrophy and cognitive impairment in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, S269-76.	0.8	47
130	Neurokinin3 receptor as a target to predict and improve learning and memory in the aged organism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 15097-15102.	7.1	50
131	APOE-Dependent Phenotypes in Subjects with Mild Cognitive Impairment Converting to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 37, 389-401.	2.6	13
132	Genome-Wide Association Study of Vascular Dementia. <i>Stroke</i> , 2012, 43, 315-319.	2.0	51
133	A Polymorphic Microsatellite Repeat within the ECE-1c Promoter Is Involved in Transcriptional Start Site Determination, Human Evolution, and Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2012, 32, 16807-16820.	3.6	17
134	Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. <i>Nature Medicine</i> , 2012, 18, 1812-1819.	30.7	359
135	An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. <i>Nature Neuroscience</i> , 2012, 15, 827-835.	14.8	647
136	A combination of galantamine and memantine modifies cognitive function in subjects with amnesic MCI. <i>Journal of Nutrition, Health and Aging</i> , 2012, 16, 544-548.	3.3	48
137	Association of N-Acetylaspartate and Cerebrospinal Fluid A β 242 in Dementia. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 393-399.	2.6	10
138	Long-Term Stability of Alzheimer's Disease Biomarker Proteins in Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 255-262.	2.6	29
139	Antidepressants act on glial cells: SSRIs and serotonin elicit astrocyte calcium signaling in the mouse prefrontal cortex. <i>Journal of Psychiatric Research</i> , 2011, 45, 242-248.	3.1	82
140	Cerebral amyloid- β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. <i>Lancet Neurology</i> , The, 2011, 10, 424-435.	10.2	491
141	Atrophy outcomes in multicentre clinical trials on Alzheimer's disease: Effect of different processing and analysis approaches on sample sizes. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 109-113.	2.6	8
142	Left Anterior Temporal Lobe Sustains Naming in Alzheimers Dementia and Mild Cognitive Impairment. <i>Current Alzheimer Research</i> , 2011, 8, 893-901.	1.4	27
143	Multicentre variability of MRI-based medial temporal lobe volumetry in Alzheimer's disease. <i>Psychiatry Research - Neuroimaging</i> , 2010, 182, 244-250.	1.8	46
144	The relation of regional cerebral perfusion and atrophy in mild cognitive impairment (MCI) and early Alzheimer's dementia. <i>Psychiatry Research - Neuroimaging</i> , 2010, 183, 44-51.	1.8	26

#	ARTICLE	IF	CITATIONS
145	Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. PLoS ONE, 2010, 5, e13950.	2.5	347
146	Early and Differential Diagnosis of Dementia and Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2009, 27, 404-417.	1.5	90
147	A Possible New Diagnostic Biomarker in Early Diagnosis of Alzheimers Disease. Current Alzheimer Research, 2009, 6, 519-524.	1.4	25
148	Measurement of ERK 1/2 in CSF from Patients with Neuropsychiatric Disorders and Evidence for the Presence of the Activated Form. Journal of Alzheimer's Disease, 2009, 18, 613-622.	2.6	18
149	Association of SORL1 gene variants with Alzheimer's disease. Brain Research, 2009, 1264, 1-6.	2.2	49
150	Astrocyte Function is Modified by Alzheimer's Disease-like Pathology in Aged Mice. Journal of Alzheimer's Disease, 2009, 18, 177-189.	2.6	71
151	Temperature and nitric oxide control spontaneous calcium transients in astrocytes. Cell Calcium, 2008, 43, 285-295.	2.4	37
152	Influence of SORL1 gene variants: Association with CSF amyloid- β products in probable Alzheimer's disease. Neuroscience Letters, 2008, 440, 68-71.	2.1	43
153	Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. Neurobiology of Aging, 2008, 29, 812-818.	3.1	94
154	Amyloid β peptide ratio 42/40 but not A β 42 correlates with phospho τ in patients with low β -and high β -CSF A β 40 load. Journal of Neurochemistry, 2007, 101, 1053-1059.	3.9	237
155	Activity-dependent ATP-waves in the Mouse Neocortex are Independent from Astrocytic Calcium Waves. Cerebral Cortex, 2006, 16, 237-246.	2.9	131
156	Zinc ions are endogenous modulators of neurotransmitter β -stimulated capacitative Ca ²⁺ entry in both cultured and <i>in situ</i> mouse astrocytes. European Journal of Neuroscience, 2005, 21, 1626-1634.	2.6	34
157	Increased Extracellular K ⁺ Concentration Reduces the Efficacy of <i>NMDA</i> -methyl-aspartate Receptor Antagonists to Block Spreading Depression-Like Depolarizations and Spreading Ischemia. Stroke, 2005, 36, 1270-1277.	2.0	76
158	Impaired Synaptic Plasticity in the Surround of Perinatally Acquired Dysplasia in Rat Cerebral Cortex. Cerebral Cortex, 2004, 14, 1081-1087.	2.9	17
159	Different Mechanisms Promote Astrocyte Ca ²⁺ Waves and Spreading Depression in the Mouse Neocortex. Journal of Neuroscience, 2003, 23, 9888-9896.	3.6	183
160	Cortical Spreading Depression Induces Proinflammatory Cytokine Gene Expression in the Rat Brain. Journal of Cerebral Blood Flow and Metabolism, 2001, 21, 218-225.	4.3	161
161	Increased Formation of Reactive Oxygen Species after Permanent and Reversible Middle Cerebral Artery Occlusion in the Rat. Journal of Cerebral Blood Flow and Metabolism, 1998, 18, 196-205.	4.3	274